PDGFRB and telomere syndrome: Anlotinib is a novel orally administered TKI targeting vascular endothelial growth factor receptor-1/2/3, PDGFR α/β, fibroblast growth factor receptor-1/2/3/4, c-Kit, and Ret (23), which demonstrates antitumor activity in patients with refractory metastatic STS, with a median PFS of 5.6 months (24).